GENETICS/GENOMICS AND DRUG EFFECTS

REFERENCES

• Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7: 201–204.
   PubMed Web of Science ®Google Scholar
• KirchheinerJ, Fuhr U, Borckmoller J. Pharmacogenetics-based therapeutic recom-mendations-ready for clinical practice? Nat Rev Drug Discov 2005; 4:639–647.
   Web of Science ®Google Scholar
• Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational stud-ies. Ann Pharmacother 2008; 42: 1017–1025.
   PubMed Web of Science ®Google Scholar
• Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortal-ity. JAMA 1997; 277: 301–306.
   PubMed Web of Science ®Google Scholar
• Zhang W, Roederer MW, Chen WQ Fan L, Zhou HH. Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics 2012; 13: 223–231.
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538–549.
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58: 521–590.
   PubMed Web of Science ®Google Scholar
• Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 2011; 12: 487–497.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Zeldin DC, Hoffman SM, Maltais U, Wain HM, Nebert DW. Compari-son of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alter-native-splice variants. Pharmacogenetics 2004; 14: 1–18.
   PubMedGoogle Scholar
• Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the geneti-cally determined differences in morphine formation. Pain 1998; 76: 27–33.
   PubMed Web of Science ®Google Scholar
• Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P. Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 30: 2827–2831.
   Web of Science ®Google Scholar
• Madadi P. Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85: 31–35.
   PubMed Web of Science ®Google Scholar
• Kwadijk-de Gijsel S, BijI MJ, Visser LE, et al. Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepres-sants. Br J Clin Pharmacol 2009; 68:221–225.
   PubMed Web of Science ®Google Scholar
• Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim JW. Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit 2006; 28: 382–387.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemo-therapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717.
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymor-phisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429–1436.
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Lash TL. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol 2011; 4: 363–377.
   PubMedGoogle Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354–362.
   PubMed Web of Science ®Google Scholar
• Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genom-ics 2010; 20: 463–465.
   PubMed Web of Science ®Google Scholar
• Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011; 306: 2221–2228.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among patients Treated With Clopidogrel Predominantly for PCI.JAMA 2010; 304: 1821-1830.
   Google Scholar
• Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363: 1704–1714.
   PubMed Web of Science ®Google Scholar
• Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovas-cular outcomes in patients with coronary artery disease treated with clopidog-rel. Heart 2012; 98: 100–108.
   PubMed Web of Science ®Google Scholar
• Li Y, Tang HL, Hu YF, Xie HG. The Gain-of-Function Variant Allele CYP2C19*17: A Double-Edged Sword Between Thrombosis and Bleeding in Clopidogrel-Treated Patients. J Thromb Haemost 2012; 10: 199–206.
   PubMed Web of Science ®Google Scholar
• Holmes MV, Perel P. Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopi-dogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306: 2704–2714.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. US Food and Drug Admin-istration. http://www.fda.gov/drugs/drugsafety/PostmarketDrugSafetylnforma-tionforPatientsandProviders/ucm203888.htm. Accessed October 26, 2011.
   Google Scholar
• Armani AM. Prasugrel: an efficacy and safety review of a new antiplatelet ther-apy option. Crit Pathw Cardiol 2010; 9: 199–202.
   Google Scholar
• Crouch MA, Colucci VJ, Howard PA, Spinier SA. P2Y12 receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome. Ann Pharmacother 2011; 45:1151–1156.
   Web of Science ®Google Scholar
• International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacoge-netic data. N Engl J Med 2009; 360: 753–764.
   Web of Science ®Google Scholar
• Epstein RS, Moyer TP, Aubert RE, O Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55: 2804–2812.
   PubMed Web of Science ®Google Scholar
• Slatter JG, Su P. Sams JP, Schaaf U, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997; 25:1157–1164.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Undevia SD, lyer L et al. Genetic variants in the UDPglucuronosyl-transferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382–1388.
   PubMed Web of Science ®Google Scholar
• Soong R, Shah N, Salto-Tellez M, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluo-rouracil-based chemotherapy. Ann Oncol 2008; 19:915–919.
   PubMed Web of Science ®Google Scholar
• Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydro-genase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322–1327.
   PubMed Web of Science ®Google Scholar
• Markman M. Pharmacogenomics of 5-Fluorouracil: Clinical Implications. Med-scape Genomic Medicine. Posted: 08/24/2011.
   Google Scholar
• Payne K, Newman W, Fargher E, Tricker K, Bruce IN, Oilier WE. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology (Oxford) 2007; 46: 727–729.
   PubMed Web of Science ®Google Scholar
• Kerb R. Implications of genetic polymorphisms in drug transporters for pharmaco-therapy Cancer Lett 2006; 234: 4–33.
   Google Scholar
• SEARCH Collaborative Group, Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008; 359: 789–799.
   PubMed Web of Science ®Google Scholar
• Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy 2007; 27: 874–887.
   PubMed Web of Science ®Google Scholar
• McDermott U, Downing JR, Stratton MR. Genomics and the Continuum of Can-cer Care. N Engl J Med 2011; 364: 340–350.
   PubMed Web of Science ®Google Scholar
• Rofaiel S, Muo EN, Mousa SA. Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmacogenomics and Personalized Medicine 2010; 3: 129–143.
   Google Scholar
• Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010; 9: 363–366.
   PubMed Web of Science ®Google Scholar
• Russmann S, Kaye JA, Jick SS, Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 2005; 60: 76–82.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to a bacavir. N Engl J Med 2008; 358: 568–579.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services FaDA, Center for Devices and Radiological Health, Guidance for Industry and FDA Staff: Pharmacogenetic Tests and Genetic Tests for Heritable Markers. Available at http://www.fda.gov/downloads/MedicaIDevices/DeviceRegulationandGuidance/GuidanceDocu-ments/UCM071075.pdf. Accessed on December 16, 2009.
   Google Scholar
• Jorgensen JT. From Blockbuster Medicine to Personalized Medicine. Pers Med 2008; 5: 55–63.
   PubMed Web of Science ®Google Scholar
• Alfirevic A. Adverse Drug Reactions and Pharmacogenomics: Recent Advances. Pers Med 2008; 5: 11–23.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. http://3wida.gov/Drugs/ScienceResearch/ResearchAreas/Pharma-cogenetics/ucm083378.htm. Accessed 1/18/2011.
   Google Scholar
• Hudson KL. Genomics, Health care, and Society. N Engl J Med 2011; 365:1033–1041.
   Web of Science ®Google Scholar
• Zhang W. A Systems Biology Approach to Pharmacogenomic Discovery, Internal Med: Open Access 20111: el 02. doi: 10.4172/ime.1000e102.
   Google Scholar
• Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA. Implications of pharma-cogenomics for drug development and clinical practice. Arch Intern Med 2005; 165: 2331–2336.
   PubMed Web of Science ®Google Scholar
• Patay BA, Topol EJ. The unmet need of education in genomic medicine. Am J Med 2012; 125: 5–6.
   Web of Science ®Google Scholar